Latest United States News

Volt Resources has secured US$5.4 million in fully government-funded support for its US graphite refinery and customer application centre. The award is positive for project funding, but the company’s ASX securities remain suspended as it works with the exchange to satisfy reinstatement requirements.

PolyNovo delivered 16.1% revenue growth and a sharp improvement in operating cash flow in FY26, despite a lower statutory profit after a prior-year tax benefit and a fire-related write-off. The ASX-listed wound-care company now expects to lodge its U.S. PMA application for NovoSorb BTM before the end of 2026.

Trek Metals has secured a nine-month option to acquire the 154-claim Matrix Manganese Project in Arizona for a total potential cash consideration of A$200,000. The deal offers a low-cost route into a US critical-minerals opportunity, but carries a significant related-party consideration because CEO Derek Marshall owns about 66.67% of the vendor.

Latrobe Magnesium is shifting its growth priority to a proposed 50 ktpa magnesium plant in South Carolina, backed by 32 ktpa of non-binding customer interest and a 20-year feedstock agreement. The project carries substantial indicative economics, but still needs funding, site acquisition, feasibility work, permits and binding offtake contracts.

JPMorgan US 100Q Equity Premium Income ETF (ASX:JPH) lifted operating profit to A$15.678 million for the year ended 30 June 2026, while net assets rose to A$106.991 million. The fund is also preparing to move its underlying exposure from a Nasdaq-listed ETF to an Irish UCITS vehicle traded in London, with total management fees and costs unchanged at 0.40% a year.

JPMorgan Global Research Enhanced Index Equity Trust reported a sharp rise in operating profit and net assets for the year ended 30 June 2026, powered largely by fair value gains across its global portfolio. Distributions also increased substantially, particularly for hedged classes, although the report does not show whether the Fund outperformed its benchmark.

JPMorgan Equity Premium Income ETF grew net assets to $167.99 million while operating profit plunged to $740,000 as fair-value losses widened. The fund is also preparing to switch its underlying ETF from NYSE Arca to the London Stock Exchange without changing its investment objective or stated total fees and costs.

Adisyn says the USPTO has allowed its third US patent application, extending its graphene deposition claims from metallic surfaces to non-metallic semiconductor materials. The allowed claims also include low-temperature processing and in-process quality checks, although commercial adoption remains unconfirmed.

Victory Metals has secured a 2,006-hectare mining lease for its North Stanmore heavy rare earths project in Western Australia. The grant removes a key tenure hurdle, but technical studies, approvals, offtake agreements and financing still stand between the project and a development decision.

Telix’s Pixclara has become the first FDA-approved FET-PET imaging drug for glioma, opening a new US diagnostic pathway for adults and children. The approval is commercially significant, but pricing, reimbursement and launch timing remain undisclosed.

Paradigm Biopharmaceuticals has drawn the remaining US$2 million available in Tranche 4 of its convertible note facility, adding approximately A$2.8 million to working capital. The funding comes as its fully enrolled Phase 3 knee osteoarthritis trial advances towards interim analysis and top-line results.

Resolution Minerals has finished its largest-ever exploration program at the Horse Heaven project in Idaho, drilling 42 diamond holes across 12,236 metres. The work sets up a substantial run of gold, tungsten and multi-element assay results, but the completed program has not yet produced new assay data in this announcement.